Cargando…

Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults

Background. High-dose inactivated influenza vaccine (IIV-HD) is an alternative to the standard-dose inactivated influenza vaccine (IIV-SD) in the United States for influenza prevention in older adults. IIV-HD improved efficacy relative to IIV-SD in a randomized controlled trial. Recent observational...

Descripción completa

Detalles Bibliográficos
Autores principales:	DiazGranados, Carlos A., Dunning, Andrew J., Robertson, Corwin A., Talbot, H. Keipp, Landolfi, Victoria, Greenberg, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826458/ https://www.ncbi.nlm.nih.gov/pubmed/26908801 http://dx.doi.org/10.1093/cid/ciw085

Ejemplares similares

1059 Expanded immunogenicity of high-dose inactivated influenza vaccine compared to standard-dose inactivated influenza vaccine in older adults
por: Diazgranados, Carlos, et al.
Publicado: (2014)

Gastrointestinal Events in High-Dose vs Standard-Dose Influenza Vaccine Recipients
por: Talbot, H Keipp, et al.
Publicado: (2018)

530 Disease Modulation in Older Adults Vaccinated with High-Dose Versus Standard-Dose Influenza Vaccine
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial
por: Dunning, Andrew J., et al.
Publicado: (2016)

Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
por: Greenberg, David P., et al.
Publicado: (2017)

LB14. Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older
por: Chang, Lee-Jah, et al.
Publicado: (2018)

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors
por: Becker, Debbie L., et al.
Publicado: (2016)

2015–2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States
por: Poehling, Katherine A, et al.
Publicado: (2018)

Safety and Immunogenicity of a Full-dose, Split-virion, Inactivated, Quadrivalent Influenza Vaccine in Healthy Children 6-35 Months of Age: A Randomized Controlled Clinical Trial
por: Robertson, Corwin A., et al.
Publicado: (2019)

Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity
por: Roy, Sreeja, et al.
Publicado: (2020)

Immunogenicity of Fractional Dose Inactivated Poliovirus Vaccine in India
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Impact of diabetes status on immunogenicity of trivalent inactivated influenza vaccine in older adults
por: Spencer, Sarah, et al.
Publicado: (2021)

Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trial
por: Schmader, Kenneth E., et al.
Publicado: (2023)

Standardisation of inactivated influenza vaccines—Learning from history
por: Wood, John M., et al.
Publicado: (2018)

160. Safety and Immunogenicity of Escalating Dose Formulations of High-dose Quadrivalent Influenza Vaccine in Children 6 Months Through < 18 Years of Age
por: Chang, Leejah, et al.
Publicado: (2020)

Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
por: Boikos, Constantina, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews
por: Carregaro, Rodrigo Luiz, et al.
Publicado: (2023)

Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time
por: Huang, Kuan-Ying A., et al.
Publicado: (2017)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

1054 Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age
por: Gorse, Geoffrey J., et al.
Publicado: (2014)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

531 Split-virion compared to Subunit Influenza Trivalent Influenza Vaccines Has Greater Effectiveness in Older Adults
por: Talbot, H. Keipp, et al.
Publicado: (2014)

Long-term immunogenicity in previously vaccinated healthcare workers with inactivated virus vaccine after SARS-CoV-2 infection or booster vaccination
por: Terbsiri, Varalee, et al.
Publicado: (2023)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
por: Lai, Kristi Tsz-Wan, et al.
Publicado: (2022)

150. Relative Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults—United States, 2015–2017
por: Doyle, Joshua, et al.
Publicado: (2018)

The Effect of Age and Recent Influenza Vaccination History on the Immunogenicity and Efficacy of 2009–10 Seasonal Trivalent Inactivated Influenza Vaccination in Children
por: Ng, Sophia, et al.
Publicado: (2013)

Enhanced Immunogenicity of a Whole-Inactivated Influenza A Virus Vaccine Using Optimised Irradiation Conditions
por: Singleton, Eve Victoria, et al.
Publicado: (2021)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
por: Pepin, Stephanie, et al.
Publicado: (2021)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
por: Li, Juan, et al.
Publicado: (2021)

Effect of aging on immunogenicity and efficacy of inactivated influenza vaccines in cotton rats Sigmodon hispidus
por: Boukhvalova, Marina S., et al.
Publicado: (2020)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Prospects of malaria vaccination in Nigeria: Anticipated challenges and lessons from previous vaccination campaigns
por: Effiong, Fortune Benjamin, et al.
Publicado: (2022)

The Potential Benefits of HPV Vaccination in Previously Infected Women
por: Schiller, John T.
Publicado: (2016)

Dendritic cell-based in vitro assays for vaccine immunogenicity
por: Vandebriel, Rob J., et al.
Publicado: (2012)

Covid-19 vaccine trials: Ethnic diversity and immunogenicity
por: Jethwa, Hannah, et al.
Publicado: (2021)

Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose
por: Dagan, Ron, et al.
Publicado: (2020)

The influenza vaccines roadmap – A better future through improved influenza vaccines
por: Hart, Peter, et al.
Publicado: (2021)

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial
por: Nunes, Marta C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_96ls109t2v2ri3m8kld544efab